Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXS AveXis	$217.83	$0.00	$65.54 ▼ $217.94	N/A	N/A	816,305 shs	222 shs
ELOX Eloxx Pharmaceuticals		$0.11	$0.00 ▼ $0.75	N/A	-1538.18	1,538 shs	N/A
IKT Inhibikase Therapeutics	$1.89 +12.5%	$1.77	$1.12 ▼ $4.20	$140.51M	0.9	191,826 shs	218,894 shs
PRME Prime Medicine	$3.55 +10.2%	$3.50	$1.11 ▼ $5.17	$477.74M	2.39	2.53 million shs	3.10 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXS AveXis	0.00%	0.00%	0.00%	0.00%	0.00%
ELOX Eloxx Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-99.99%
IKT Inhibikase Therapeutics	0.00%	-1.75%	-12.95%	-5.08%	+15.86%
PRME Prime Medicine	-0.62%	-11.54%	-28.92%	+149.61%	-26.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXS AveXis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.7616 of 5 stars	3.3	2.0	0.0	0.0	2.2	0.0	0.6
PRME Prime Medicine	2.9212 of 5 stars	3.4	1.0	0.0	0.0	1.8	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXS AveXis	0.00	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	243.92% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	151.17% Upside

Current Analyst Ratings Breakdown

Latest AVXS, ELOX, PRME, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXS AveXis	N/A	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PRME Prime Medicine	$4.96M	96.30	N/A	N/A	$1.37 per share	2.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXS AveXis	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	-$36.06M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXS AveXis	N/A	N/A	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	40.73%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXS AveXis	N/A	N/A	N/A
ELOX Eloxx Pharmaceuticals	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXS AveXis	84.14%
ELOX Eloxx Pharmaceuticals	2.90%
IKT Inhibikase Therapeutics	3.81%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
AVXS AveXis	18.60%
ELOX Eloxx Pharmaceuticals	20.20%
IKT Inhibikase Therapeutics	7.30%
PRME Prime Medicine	22.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXS AveXis	N/A	N/A	N/A	Optionable
ELOX Eloxx Pharmaceuticals	30	3.14 million	2.51 million	Not Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable

AVXS, ELOX, PRME, and IKT Headlines

Recent News About These Companies

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $8.92

August 21 at 2:18 AM | americanbankingnews.com

Positive Signs As Multiple Insiders Buy Prime Medicine Stock

August 20 at 7:34 AM | uk.finance.yahoo.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Analysts

August 19 at 3:50 AM | marketbeat.com

Analysts Set Expectations for Prime Medicine FY2025 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimates for Prime Medicine Cut by HC Wainwright

August 16, 2025 | marketbeat.com

HC Wainwright Cuts Earnings Estimates for Prime Medicine

August 16, 2025 | americanbankingnews.com

Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00

August 10, 2025 | marketbeat.com

Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

August 8, 2025 | tipranks.com

PRME Revenue Misses by 73%

August 8, 2025 | aol.comA

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Trading Down 6.7% - Here's What Happened

August 6, 2025 | marketbeat.com

Prime Medicine Holds Special Stockholder Meeting

August 5, 2025 | tipranks.com

Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity

August 5, 2025 | marketbeat.com

Friday’s Insider Trades: Key Buys and Sells in US Stocks Revealed

August 4, 2025 | investing.com

Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares of Prime Medicine, Inc. (NYSE:PRME) Stock

August 2, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares

August 2, 2025 | insidertrades.com

Prime Medicine Halts Sales Agreement Prospectus

August 1, 2025 | theglobeandmail.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

August 1, 2025 | finance.yahoo.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

August 1, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Shares Gap Down - Here's Why

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXS, ELOX, PRME, and IKT Company Descriptions

AveXis NASDAQ:AVXS

AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.

Eloxx Pharmaceuticals NASDAQ:ELOX

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Inhibikase Therapeutics NYSE:IKT

$1.89 +0.21 (+12.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.88 0.00 (-0.26%)

As of 04:10 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Prime Medicine NYSE:PRME

$3.55 +0.33 (+10.25%)

Closing price 04:00 PM Eastern

Extended Trading

$3.59 +0.04 (+1.15%)

As of 07:14 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time